Trial Profile
Randomized Phase II Study of Cisplatin Plus Radiotherapy Versus Durvalumab Plus Radiotherapy Followed by Adjuvant Durvalumab Versus Durvalumab Plus Radiotherapy Followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Cisplatin
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 17 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 25 Mar 2020 Planned End Date has been changed to 31 Jul 2026.
- 25 Mar 2020 Planned primary completion date has been changed to 31 Jan 2026.